<?xml version="1.0" encoding="UTF-8"?>
<p>Phase III trials have suggested high rate of protection among partial immune individuals, but high rates of hospitalizations in small children who were seronegative prior to the vaccination (Aguiar et al., 
 <xref rid="B3" ref-type="bibr">2016</xref>).
</p>
